دورية أكاديمية

High mobility group box 1, ATP, lipid mediators, and tissue factor are elevated in COVID-19 patients: HMGB1 as a biomarker of worst prognosis.

التفاصيل البيبلوغرافية
العنوان: High mobility group box 1, ATP, lipid mediators, and tissue factor are elevated in COVID-19 patients: HMGB1 as a biomarker of worst prognosis.
المؤلفون: Vicentino ARR; Programa de Imunobiologia, Instituto de Biofísica Carlos Chagas Filho, Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil., Fraga-Junior VDS; Programa de Imunobiologia, Instituto de Biofísica Carlos Chagas Filho, Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil., Palazzo M; Programa de Imunobiologia, Instituto de Biofísica Carlos Chagas Filho, Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil., Tasmo NRA; Programa de Imunobiologia, Instituto de Biofísica Carlos Chagas Filho, Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil., Rodrigues DAS; Programa de Imunobiologia, Instituto de Biofísica Carlos Chagas Filho, Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil., Barroso SPC; Molecular Biology Laboratory, Laboratório de Biologia Molecular, Instituto de Pesquisas Biomédicas, Hospital Naval Marcílio Dias, Rio de Janeiro, Brazil., Ferreira SN; Molecular Biology Laboratory, Laboratório de Biologia Molecular, Instituto de Pesquisas Biomédicas, Hospital Naval Marcílio Dias, Rio de Janeiro, Brazil., Neves-Borges AC; Department of Botanic, Departamento de Botânica, Instituto de Biociências, Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro, Brazil., Allonso D; Departamento de Biotecnologia Farmacêutica, Faculdade de Farmácia, Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil., Fantappié MR; Programa de Biologia Molecular e Biotecnologia, Instituto de Bioquímica Médica Leopoldo de Meis, Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil., Scharfstein J; Programa de Imunobiologia, Instituto de Biofísica Carlos Chagas Filho, Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil., Oliveira AC; Programa de Imunobiologia, Instituto de Biofísica Carlos Chagas Filho, Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil., Vianna-Jorge R; Programa de Farmacologia e Inflamação, Instituto de Ciências Biomédicas, Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil., Vale AM; Programa de Imunobiologia, Instituto de Biofísica Carlos Chagas Filho, Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil., Coutinho-Silva R; Programa de Imunobiologia, Instituto de Biofísica Carlos Chagas Filho, Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil., Savio LEB; Programa de Imunobiologia, Instituto de Biofísica Carlos Chagas Filho, Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil., Canetti C; Programa de Imunobiologia, Instituto de Biofísica Carlos Chagas Filho, Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil., Benjamim CF; Programa de Imunobiologia, Instituto de Biofísica Carlos Chagas Filho, Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
المصدر: Clinical and translational science [Clin Transl Sci] 2023 Apr; Vol. 16 (4), pp. 631-646. Date of Electronic Publication: 2023 Jan 24.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1752-8062 (Electronic) Linking ISSN: 17528054 NLM ISO Abbreviation: Clin Transl Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Malden, MA : WileyBlackwell Pub., 2008-
مواضيع طبية MeSH: COVID-19*/diagnosis , HMGB1 Protein*, Humans ; Thromboplastin ; Biomarkers ; Prognosis ; Lipids ; Adenosine Triphosphate
مستخلص: The severe acute respiratory syndrome coronavirus 2, the agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic, has spread worldwide since it was first identified in November 2019 in Wuhan, China. Since then, progress in pathogenesis linked severity of this systemic disease to the hyperactivation of network of cytokine-driven pro-inflammatory cascades. Here, we aimed to identify molecular biomarkers of disease severity by measuring the serum levels of inflammatory mediators in a Brazilian cohort of patients with COVID-19 and healthy controls (HCs). Critically ill patients in the intensive care unit were defined as such by dependence on oxygen supplementation (93% intubated and 7% face mask), and computed tomography profiles showing ground-glass opacity pneumonia associated to and high levels of D-dimer. Our panel of mediators included HMGB1, ATP, tissue factor, PGE 2 , LTB 4 , and cys-LTs. Follow-up studies showed increased serum levels of every inflammatory mediator in patients with COVID-19 as compared to HCs. Originally acting as a transcription factor, HMGB1 acquires pro-inflammatory functions following secretion by activated leukocytes or necrotic tissues. Serum levels of HMGB1 were positively correlated with cys-LTs, D-dimer, aspartate aminotransferase, and alanine aminotransferase. Notably, the levels of the classical alarmin HMGB1 were higher in deceased patients, allowing their discrimination from patients that had been discharged at the early pulmonary and hyperinflammatory phase of COVID-19. In particular, we verified that HMGB1 levels above 125.4 ng/ml is the cutoff that distinguishes patients that are at higher risk of death. In conclusion, we propose the use of serum levels of HMGB1 as a biomarker of severe prognosis of COVID-19.
(© 2023 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.)
References: EClinicalMedicine. 2021 Aug;38:101019. (PMID: 34308300)
Biochem Biophys Res Commun. 2015 Mar 20;458(4):771-6. (PMID: 25681768)
Biochim Biophys Acta Gen Subj. 2020 Jan;1864(1):129461. (PMID: 31676289)
Heart Rhythm. 2020 Nov;17(11):1984-1990. (PMID: 32599178)
Am J Trop Med Hyg. 2021 May 03;105(1):73-80. (PMID: 33939645)
JAMA Netw Open. 2021 Jan 4;4(1):e2036142. (PMID: 33502487)
Mucosal Immunol. 2019 May;12(3):679-690. (PMID: 30664709)
Med Sci Monit. 2020 Nov 01;26:e928996. (PMID: 33177481)
Front Immunol. 2018 Sep 12;9:1979. (PMID: 30258438)
EMBO J. 2003 Oct 15;22(20):5551-60. (PMID: 14532127)
Sci Rep. 2021 May 21;11(1):10681. (PMID: 34021206)
J Leukoc Biol. 2009 Sep;86(3):655-62. (PMID: 19564572)
Cell. 2021 Apr 1;184(7):1671-1692. (PMID: 33743212)
Nature. 2022 Mar;603(7902):587-598. (PMID: 35090163)
Proc Natl Acad Sci U S A. 2021 Jun 29;118(26):. (PMID: 34108245)
J Leukoc Biol. 2020 Jul;108(1):17-41. (PMID: 32534467)
Travel Med Infect Dis. 2021 Mar-Apr;40:101995. (PMID: 33631340)
Cell Mol Immunol. 2020 Sep;17(9):992-994. (PMID: 32620787)
Allergy. 2020 Oct;75(10):2445-2476. (PMID: 32584441)
J Clin Virol. 2012 Nov;55(3):214-9. (PMID: 22884669)
Cell Host Microbe. 2020 Jun 10;27(6):863-869. (PMID: 32464098)
JAMA. 2020 Oct 6;324(13):1307-1316. (PMID: 32876695)
Med Intensiva (Engl Ed). 2022 Mar;46(3):166-168. (PMID: 35012891)
Immunity. 2018 Oct 16;49(4):740-753.e7. (PMID: 30314759)
J Cell Physiol. 2022 Aug;237(8):3394-3407. (PMID: 35754396)
J Allergy Clin Immunol. 2021 Aug;148(2):368-380.e3. (PMID: 34111453)
FASEB J. 2006 Aug;20(10):1727-9. (PMID: 16807371)
Scand J Immunol. 2013 May;77(5):350-60. (PMID: 23488692)
Blood. 2016 Nov 17;128(20):2435-2449. (PMID: 27574188)
Blood. 2020 Sep 10;136(11):1330-1341. (PMID: 32678428)
Cell. 2021 Jan 7;184(1):76-91.e13. (PMID: 33147444)
Science. 2020 Sep 4;369(6508):1255-1260. (PMID: 32703910)
J Immunol. 2022 Jul 15;209(2):250-261. (PMID: 35768148)
Biochem Eng J. 2022 Aug;186:108537. (PMID: 35874089)
Clin Transl Sci. 2023 Apr;16(4):631-646. (PMID: 36631939)
Heliyon. 2020 Dec 07;6(12):e05672. (PMID: 33313438)
Lancet. 2020 Feb 15;395(10223):497-506. (PMID: 31986264)
Arthritis Res Ther. 2010;12(4):R165. (PMID: 20799933)
Semin Immunol. 2018 Aug;38:40-48. (PMID: 29530410)
Lung. 2021 Jun;199(3):239-248. (PMID: 34050796)
J Heart Lung Transplant. 2020 May;39(5):405-407. (PMID: 32362390)
Nature. 2002 Jul 11;418(6894):191-5. (PMID: 12110890)
BMC Med. 2022 Jan 14;20(1):26. (PMID: 35027067)
Virus Evol. 2021 Oct 01;7(2):veab087. (PMID: 34725568)
Cells. 2020 Jul 22;9(8):. (PMID: 32707842)
BMC Infect Dis. 2021 Aug 21;21(1):855. (PMID: 34418980)
Curr Res Transl Med. 2020 Nov;68(4):149-150. (PMID: 32917573)
المشرفين على المادة: 9035-58-9 (Thromboplastin)
0 (HMGB1 Protein)
0 (Biomarkers)
0 (Lipids)
8L70Q75FXE (Adenosine Triphosphate)
تواريخ الأحداث: Date Created: 20230111 Date Completed: 20230412 Latest Revision: 20230511
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC10087071
DOI: 10.1111/cts.13475
PMID: 36631939
قاعدة البيانات: MEDLINE
الوصف
تدمد:1752-8062
DOI:10.1111/cts.13475